1. Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.
- Author
-
Parikh C, Janakiraman V, Wu WI, Foo CK, Kljavin NM, Chaudhuri S, Stawiski E, Lee B, Lin J, Li H, Lorenzo MN, Yuan W, Guillory J, Jackson M, Rondon J, Franke Y, Bowman KK, Sagolla M, Stinson J, Wu TD, Wu J, Stokoe D, Stern HM, Brandhuber BJ, Lin K, Skelton NJ, and Seshagiri S
- Subjects
- Allosteric Regulation drug effects, Allosteric Regulation genetics, Animals, Cell Line, Tumor, Cell Membrane drug effects, Cell Membrane enzymology, Cell Transformation, Neoplastic drug effects, Cell Transformation, Neoplastic genetics, Cell Transformation, Neoplastic pathology, Enzyme Activation drug effects, Humans, Mice, Models, Molecular, Mutant Proteins metabolism, Mutation genetics, NIH 3T3 Cells, Protein Binding drug effects, Protein Binding genetics, Protein Kinase Inhibitors pharmacology, Protein Transport drug effects, Proto-Oncogene Proteins c-akt metabolism, Signal Transduction drug effects, Signal Transduction genetics, Neoplasms enzymology, Neoplasms genetics, Oncogenes genetics, Proto-Oncogene Proteins c-akt chemistry, Proto-Oncogene Proteins c-akt genetics
- Abstract
The protein kinase v-akt murine thymoma viral oncogene homolog (AKT), a key regulator of cell survival and proliferation, is frequently hyperactivated in human cancers. Intramolecular pleckstrin homology (PH) domain-kinase domain (KD) interactions are important in maintaining AKT in an inactive state. AKT activation proceeds after a conformational change that dislodges the PH from the KD. To understand these autoinhibitory interactions, we generated mutations at the PH-KD interface and found that most of them lead to constitutive activation of AKT. Such mutations are likely another mechanism by which activation may occur in human cancers and other diseases. In support of this likelihood, we found somatic mutations in AKT1 at the PH-KD interface that have not been previously described in human cancers. Furthermore, we show that the AKT1 somatic mutants are constitutively active, leading to oncogenic signaling. Additionally, our studies show that the AKT1 mutants are not effectively inhibited by allosteric AKT inhibitors, consistent with the requirement for an intact PH-KD interface for allosteric inhibition. These results have important implications for therapeutic intervention in patients with AKT mutations at the PH-KD interface.
- Published
- 2012
- Full Text
- View/download PDF